AUNA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AUNA exhibits a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The stock appears undervalued with a current price of $5.66 versus a Graham Number of $12.0, suggesting defensive fair value, though growth metrics are weak with negative earnings and revenue growth. Profitability margins and ROE are positive, but high debt/equity and declining earnings raise concerns. Analysts recommend a 'buy' with a target price of $8.77, implying upside potential, but recent price volatility and deteriorating fundamentals temper bullishness.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AUNA vs LLY: Head-to-Head Comparison
This page compares Auna SA (AUNA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.